

FIGURE 1




FIGURE 2

Category	Lexical Element	Lexical Element	Lexical Element
Risk factor (RF) patient history			
Risk due to past history			
RF patient ADR history	Sepsis	Hypersensitivity	Hypersensitivity
RF patient family history			
RF patient concurrent condition			
Risk due to current disease			
RF past drug		Enbrel	<Enbrel component>
RF past drug class			
RF concomitant drug			
RF concomitant drug class			
RF drug-in-question (DIQ) class	DMARD	DMARD	DMARD
RF DIQ	Enbrel (etanercept)	Enbrel (etanercept)	Enbrel (etanercept)
RF difference of gender			
RF age			
Outcome	Sepsis	Hypersensitivity	Hypersensitivity
Outcome origin			
Notes on outcome and resolution			
Prescribing action for DIQ	Contraindication	Contraindication	Contraindication
Follow-up actions			
Follow-up actions cont'd			
Conditional follow-up actions			
FUA condition			
FUA conditional action			
Instructions to patient			
Conditional instructions to patient			
ITP condition			
ITP conditional action			
What to remain alert for			
Not to be used as alternate therapy for			
Parameters to monitor			
What to test or check			
When to test or check			
Why/what to consider			
Prescribing notes to Physician			

FIGURE 3

Category	Lexical Element	Lexical Element
Risk factor (RF) patient history		
Risk due to past history		
RF patient ADR history		
RF patient family history		
RF patient concurrent condition		
Risk due to current disease		
RF past drug		
RF past drug class		
RF concomitant drug		
RF concomitant drug class		
RF drug-in-question (DIQ) class	DMARD	DMARD
RF DIQ	Enbrel	Enbrel
RF difference of gender		
RF age		
Outcome	New infection	sepsis
Outcome origin		
Notes on outcome and resolution		
Prescribing action for DIQ	Continue	Discontinue
Follow-up actions	Monitor closely	
Follow-up actions cont'd		
Conditional follow-up actions	Discontinue if new infection becomes serious	
FUA condition		
FUA conditional action		
Instructions to patient		
Conditional instructions to patient		
ITP condition		
ITP conditional action		
What to remain alert for		
Not to be used as alternate therapy for		
Parameters to monitor		
What to test or check		
When to test or check		
Why/what to consider		
Prescribing notes to Physician		

FIGURE 4

Figure 5: Sample of mapping a conditional text statement to a rule structure, using dictionary terms

Label Text:

Celebrex should not be given to patients who have demonstrated allergic-type reactions to sulfonamides.

Risk Category			
Risk Factor Patient past history			
Risk Factor Patient ADR history		Allergic-type reactions	
Risk factor Patient family history			
Risk Factor Patient concurrent condition			
Risk factor Past drug			
Risk factor Past Drug Class		Sulfonamides	
Risk Factor Concomitant Drug			
Risk Factor Concomitant drug class			
Risk Factor Drug-in-Question Class			
Risk factor Drug-in-Question	Celebrex		
Outcome			
Outcome Origin			
Additional Notes on Outcome and Resolution			
Prescribing Action for Drug-in-Question	Contraindicated		
Follow-up Actions			
Follow-up Actions cont'd			
Conditional Follow-up Actions			
FUA Condition			
FUA Conditional action			
Instructions to Patient			
Conditional Instructions to Patient			
IITP Condition			
IITP Conditional action			
What to Remain Alert For			
Not to be used as Alternate Therapy For			
Parameters to Monitor			
What to Test/Check			
When to Test/Check			
Why/What to Consider			
Additional Prescribing Note to Physician			
Note General			


Label Text:

Risk Category			
Risk Factor Patient past history			
Risk Factor Patient ADR history			Rhinitis; rhinitis with nasal polyps; severe bronchospasm
Risk factor Patient family history			
Risk Factor Patient concurrent condition			
Risk factor Past drug			Aspirin triad
Risk factor Past Drug Class			NSAIDs
Risk Factor Concomitant Drug			
Risk Factor Concomitant drug class			
Risk Factor Drug-in-Question Class			NSAIDs
Risk factor Drug-in-Question	Celebrex		
Outcome			
Outcome Origin			
Add'l Notes on Outcome and Resolution	Potentially fatal	bronchospasm	
Prescribing Action for Drug-in-Question			
Follow-up Actions			Inform patients
Follow-up Actions cont'd			
Conditional Follow-up Actions			
FUA Condition			
FUA Conditional action			
Instructions to Patient			
Conditional Instructions to Patient		If anaphylactoid reaction seek emergency help	
ITP Condition	Anaphylactoid reaction		
ITP Conditional action		Seek emergency help	
What to Remain Alert For			
Not to be used as Alternate Therapy For			
Parameters to Monitor			
What to Test/Check			
When to Test/Check			
Why/What to Consider			
Additional Prescribing Note to Physician			
Note General			


[illegible]

Year	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	


a) Celebrex should not be given to patients with the aspirin triad.



8b) The symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAID's.



c) Emergency help should be sought in cases where anaphylactoid reactions occur.






FIGURE 9

App ID=09683828




Figure 10